envoplakin CRISPR/Cas9 KO Plasmid (m): sc-420248
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- envoplakin CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the envoplakin genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: envoplakin Antibody (F-4): sc-137033
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
envoplakin CRISPR/Cas9 KO Plasmid (m) | sc-420248 | 20 µg | $397.00 |
Overview
Mouse Evpl encodes envoplakin, a plakin family cytolinker that participates in assembly and stabilization of the cornified envelope in stratified epithelia. Envoplakin scaffolds protein–protein interactions that connect intermediate filaments, desmosomal junction components, and membrane-associated complexes, supporting epidermal and mucosal barrier integrity during differentiation. Through its role in cytoskeletal organization and junctional maturation, EVPL is commonly used to interrogate epithelial homeostasis, wound responses, and stress-induced remodeling processes. Altered expression or organization of cornified envelope proteins, including envoplakin, has been associated with barrier dysfunction and inflammatory skin phenotypes, making EVPL relevant to mechanistic studies of epithelial disease biology.
envoplakin CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Evpl gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Evpl together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Evpl open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish envoplakin protein expression.
This CRISPR knockout system enables efficient generation of Evpl-deficient cell models for investigation of envoplakin signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Evpl exon(s) critical for envoplakin function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Evpl genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by envoplakin CRISPR/Cas9 KO Plasmid (m) and envoplakin CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Evpl locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by envoplakin HDR Plasmid (m) and envoplakin HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Evpl homology arms to support homology-directed repair at defined Evpl target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.